Innoviva Inc INVA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INVA is a good fit for your portfolio.
News
-
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
-
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
-
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
-
FDA approves Innoviva's bacterial pneumonia treatment
-
FDA Approves Innoviva's Bacterial Pneumonia Treatment
-
Innoviva Shares Halted as FDA Panel Reviews Sulbactam-Durlobactam
Trading Information
- Previous Close Price
- $15.23
- Day Range
- $15.09–15.37
- 52-Week Range
- $11.37–16.80
- Bid/Ask
- $15.04 / $15.63
- Market Cap
- $960.91 Mil
- Volume/Avg
- 403,984 / 713,309
Key Statistics
- Price/Earnings (Normalized)
- 9.28
- Price/Sales
- 4.26
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 7.94%
Company Profile
Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 112
- Website
- https://www.inva.com
Competitors
Valuation
Metric
|
INVA
|
PFE
|
AZN
|
---|---|---|---|
Price/Earnings (Normalized) | 9.28 | 14.77 | 20.68 |
Price/Book Value | 1.43 | 1.72 | 6.33 |
Price/Sales | 4.26 | 2.79 | 5.01 |
Price/Cash Flow | 7.98 | 14.11 | 23.65 |
Price/Earnings
INVA
PFE
AZN
Financial Strength
Metric
|
INVA
|
PFE
|
AZN
|
---|---|---|---|
Quick Ratio | 7.28 | 0.58 | 0.58 |
Current Ratio | 9.03 | 0.91 | 0.82 |
Interest Coverage | 10.31 | 0.74 | 5.15 |
Quick Ratio
INVA
PFE
AZN
Profitability
Metric
|
INVA
|
PFE
|
AZN
|
---|---|---|---|
Return on Assets (Normalized) | 14.79% | 4.98% | 59.78% |
Return on Equity (Normalized) | 29.29% | 10.90% | 157.53% |
Return on Invested Capital (Normalized) | 16.71% | 7.28% | 88.21% |
Return on Assets
INVA
PFE
AZN
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zpbcrxbz | Nht | $572.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xfmfyryc | Vxzxzv | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fmgyzwcm | Yfdmqrl | $99.2 Bil | |
MRNA
| Moderna Inc | Gbmvhhw | Nthx | $42.7 Bil | |
ARGX
| argenx SE ADR | Rcnbvnhz | Ybgt | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Gblwsmmb | Cmrx | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wrrgzbznp | Ycqhv | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xchkrvrs | Rwllj | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jmbvsmlhx | Lnvsdy | $12.7 Bil | |
INCY
| Incyte Corp | Cfnpnswx | Jdnxlc | $11.9 Bil |